Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
CMPI was delisted on the 27th of May, 2022.
37 hedge funds and large institutions have $187M invested in Checkmate Pharmaceuticals, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 37 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VP
venBio Partners
San Francisco,
California
|
+$47.1M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$46.2M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$27.8M |
| 4 |
MVM
Medicxi Ventures Management
St. Helier,
Jersey
|
+$19.2M |
| 5 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$17.1M |
Top Sellers
CMPI Hedge Fund Activity: Q3 2020 in Review
37 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) for Q3 2020, worth a combined $187M.
Buyers outnumbered sellers: 37 funds opened new CMPI positions and 0 closed out — a net gain of 37 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was venBio Partners, opening a new position worth an estimated $47.1M.
- 37 institutional investors held Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $187M of Checkmate Pharmaceuticals, Inc. Common Stock stock for Q3 2020.
- 37 funds opened new Checkmate Pharmaceuticals, Inc. Common Stock positions in Q3 2020 and 0 closed out, a net change of +37 holders.
- The largest Checkmate Pharmaceuticals, Inc. Common Stock buyer in Q3 2020 was venBio Partners, an estimated $47.1M added.
Based on aggregated 13F filings for Q3 2020.